KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ORTHOPEDIATRICS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.03+0.08 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $529.79M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
73.1%−4.4 pts over 5 years
Operating margin
-16.6%+21.0 pts over 5 years
Net margin
-16.8%+29.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +15.4% | +24.6% | +27.2% | +22.5% | |
| Gross profit | +16.2% | +24.0% | +25.7% | +23.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 11.0% | -17.5% | -11.3% | |
| Return on assets | – | -13.1% | -8.1% | |
| Current ratio | 2.87 | 4.52 | 5.55 | |
| Debt to equity | -0.27 | 0.01 | 0.29 | |
| Net debt to EBITDA | -3.77× | 1.54× | -4.53× | |
| Interest coverage | -4.2× | -7.8× | -6.5× | |
| Inventory turnover | – | 0.4× | 0.5× | |
| Capex to revenue | 11.7% | 14.8% | 4.7% | |
| Diluted shares | 2M | 18M | 23M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Orthopediatrics generated $93.77M from operations and spent $60.39M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$93.77M
Used
$60.39M
Capital expenditure$60.39M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-16.8%
×Asset turnover0.48×
×Equity multiplier1.40×
=Return on equity, FY2025-11.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -16.8% | 0.48× | 1.40× | -11.3% |
| FY2024 | -18.5% | 0.45× | 1.25× | -10.3% |
| FY2023 | -14.1% | 0.34× | 1.15× | -5.6% |
| FY2022 | 1.0% | 0.33× | 1.21× | 0.4% |
| FY2021 | -16.6% | 0.31× | 1.36× | -7.1% |
| FY2020 | -46.3% | 0.28× | 1.33× | -17.5% |
| FY2019 | -18.9% | 0.49× | 1.31× | -12.3% |
| FY2018 | -20.9% | 0.59× | 1.50× | -18.6% |
| FY2017 | -19.6% | 0.81× | -6.34× | 100.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$39.65M
- Cash generatingOperating cash flow above zero-$4.85M
- Return on assets improvedROA up on the prior year-8.6% → -8.4%
- Earnings backed by cashOperating cash flow above net income-$4.85M vs -$39.65M
- Less leverageLong-term debt to assets fell15.4% → 19.6%
- Better liquidityCurrent ratio rose6.98 → 5.55
- No dilutionShare count did not rise23M → 23M
- Gross margin improvedGross margin up on the prior year72.58% → 73.05%
- More efficientAsset turnover rose0.47 → 0.50